PlaqueTec is capitalising on the lack of biomarkers available to inform the development of new cardiovascular drugs. Its proprietary technology can be used to:
- assess the performance and potential differentiation of existing drugs;
- facilitate the development of new drugs;
- better understand mechanisms for treatment of CAD;
- develop patient-specific information and more accurately predict the risk of heart attack; and
- stratify target populations for specific drug therapies.
PlaqueTec is currently providing pharma with access to its unique biomarker data.